WO2004093907A3 - Therapeutic agents for treating dermatitis, alopecia and itching and transgenic animals for evaluating such therapeutic agents - Google Patents

Therapeutic agents for treating dermatitis, alopecia and itching and transgenic animals for evaluating such therapeutic agents Download PDF

Info

Publication number
WO2004093907A3
WO2004093907A3 PCT/JP2004/005580 JP2004005580W WO2004093907A3 WO 2004093907 A3 WO2004093907 A3 WO 2004093907A3 JP 2004005580 W JP2004005580 W JP 2004005580W WO 2004093907 A3 WO2004093907 A3 WO 2004093907A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agents
alopecia
itching
evaluating
transgenic animals
Prior art date
Application number
PCT/JP2004/005580
Other languages
French (fr)
Other versions
WO2004093907A2 (en
Inventor
Tomoaki Hoshino
Original Assignee
Tomoaki Hoshino
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2004022314A external-priority patent/JP2004340921A/en
Application filed by Tomoaki Hoshino filed Critical Tomoaki Hoshino
Publication of WO2004093907A2 publication Critical patent/WO2004093907A2/en
Publication of WO2004093907A3 publication Critical patent/WO2004093907A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)

Abstract

Using the transgenic mouse, the effect of an agent to be tested on dermatitis for which autoimmune dermatitis is a typical example and/or alopecia and/or itch can be examined, and an agent for preventing / treating dermatitis, alopecia or itch can be provided.
PCT/JP2004/005580 2003-04-23 2004-04-19 Therapeutic agents for treating dermatitis, alopecia and itching and transgenic animals for evaluating such therapeutic agents WO2004093907A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003118055 2003-04-23
JP2003-118055 2003-04-23
JP2004-022314 2004-01-29
JP2004022314A JP2004340921A (en) 2003-01-30 2004-01-29 Method for evaluating therapeutic agent for dermatitis, depilation and pruritus, prevention or therapeutic agent of dermatitis, depilation and pruritus, transgenic animal

Publications (2)

Publication Number Publication Date
WO2004093907A2 WO2004093907A2 (en) 2004-11-04
WO2004093907A3 true WO2004093907A3 (en) 2005-02-24

Family

ID=33312628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/005580 WO2004093907A2 (en) 2003-04-23 2004-04-19 Therapeutic agents for treating dermatitis, alopecia and itching and transgenic animals for evaluating such therapeutic agents

Country Status (1)

Country Link
WO (1) WO2004093907A2 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068223A (en) * 1985-09-09 1991-11-26 Board Of Regents, University Of Texas System Hydrophobic peptide esters and amides
WO1994007366A1 (en) * 1992-09-30 1994-04-14 Tykocinski Mark L Pp14-based therapy
US5817628A (en) * 1992-12-02 1998-10-06 The Rockefeller University Dynorphin a suppression of natural killer cell activity
WO2000002923A1 (en) * 1998-07-09 2000-01-20 Nickoloff Brian J Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
WO2001019373A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
EP1092773A2 (en) * 1999-10-15 2001-04-18 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Polypeptide and uses thereof
GB2367553A (en) * 2000-09-04 2002-04-10 Novartis Ag Pharmaceutically Active Macrocycles
WO2003086317A2 (en) * 2002-04-10 2003-10-23 Protalex, Inc. Protein a compositions and methods of use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068223A (en) * 1985-09-09 1991-11-26 Board Of Regents, University Of Texas System Hydrophobic peptide esters and amides
WO1994007366A1 (en) * 1992-09-30 1994-04-14 Tykocinski Mark L Pp14-based therapy
US5817628A (en) * 1992-12-02 1998-10-06 The Rockefeller University Dynorphin a suppression of natural killer cell activity
WO2000002923A1 (en) * 1998-07-09 2000-01-20 Nickoloff Brian J Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
WO2001019373A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
EP1092773A2 (en) * 1999-10-15 2001-04-18 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Polypeptide and uses thereof
GB2367553A (en) * 2000-09-04 2002-04-10 Novartis Ag Pharmaceutically Active Macrocycles
WO2003086317A2 (en) * 2002-04-10 2003-10-23 Protalex, Inc. Protein a compositions and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE ADISNEWS [online] 8 August 2001 (2001-08-08), "Symposia: Update on biotech drugs for psoriasis.", XP002291734, retrieved from STN Database accession no. 2001:501 *
INPHARMA ISSN: 1173-8324, 20 July 2001 (2001-07-20) *
KATHLEEN PARFITT (ED): "Martindale The complete drug reference 32nd Edition", 1999, PHARMACEUTICAL PRESS, LONDON UK, XP002291733 *
LESKO M J ET AL: "THE EFFECT OF TOPICAL STEROID APPLICATION ON NATURAL KILLER CELL ACTIVITY", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 19, no. 6, 1989, pages 633 - 636, XP009034952, ISSN: 0954-7894 *

Also Published As

Publication number Publication date
WO2004093907A2 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
PT1682126E (en) Substituted benzazoles and use thereof as inhibitors of raf kinase
BR0316203A (en) Use of an antiallergic agent and a steroid to treat allergic rhinitis
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
TR200102499T2 (en) As a combination therapy in the treatment of neoplasia, a cyclooxygenase-2 inhibitor and a method of using one or more antineoplastic agents
GB2421260B (en) Well treating compositions for slow release of treatment agents and methods of using the same
IL181740A0 (en) THERAPEUTIC AGENTS TARGETING THE NCca-atp CHANNEL AND METHODS OF USE THEREOF
WO2006034048A3 (en) Therapeutic agents targeting the ncca-atp channel and methods of use thereof
ATE387215T1 (en) AGENT FOR PREVENTING OR TREATING PSORIASIS HAVING AN IL-6 ANTAGONIST AS THE ACTIVE INGREDIENT
WO2004080430A3 (en) Methods of improving skin quality
EA200600689A1 (en) SUBSTITUTED BENZEZOLES AND THEIR APPLICATION AS RAF KINASE INHIBITORS
WO2007073505A3 (en) Trpa1 inhibitors for treating pain
WO2005041891A3 (en) Neutrophil activation by immune response modifier compounds
DK1392131T3 (en) Skin Diet Feeds for Pets
WO2004100987A3 (en) Methods of using il-1 antagonists to treat neointimal hyperplasia
DE60206198T2 (en) TETRAHYDROCHINOLINE DERIVATIVES AS MUSCARIN AGONISTS
WO2006041800A3 (en) 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated kv1.3 potassium channel
WO2004110151A8 (en) Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
WO2002091858A8 (en) Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
BR0011225A (en) Agent to treat dry eyes, its method and use
WO2007001395A3 (en) Prevention and treatment of influenza with glutamine antagonist agents
WO2006124770A3 (en) Treatment of sepsis and inflammation with alpha2a adrenergic antagonists
BR9906998A (en) Method and compositions to reduce dermatological aging and to reduce bruises
WO2004041214A3 (en) Methods for treating migraine
WO2008067158A3 (en) METHOD TO PROMOTE HAIR GROWTH AND/OR DELAY OR TREAT HAIR LOSS BY ADMINISTERING A TGF-β ANTAGONIST OR INHIBITOR

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase